Veradermics grants R&D head 9,650 RSUs, 19,300 options
Veradermics’ Chief R&D Officer received time-based RSUs and stock options that vest over four years starting in 2027.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Veradermics, Inc (MANE) reported that Chief R&D Officer David Hollander received equity awards on September 1, 2026. He was granted 9,650 shares of Common Stock in the form of restricted stock units and a stock option for 19,300 shares at an exercise price of $97.51 per share, both held directly.
The RSUs vest 25% on each of September 1, 2027, 2028, 2029, and 2030, subject to continued service. The option vests 25% on September 1, 2027, with the remaining shares vesting in equal monthly installments over the following 36 months and expires on September 1, 2036.
Insider Trade Summary
Grant/Award: 28,950 shares
Grant/Award
2 txns
Insider
Hollander David
Role
Chief R&D Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) F2 | 19,300 | $0.00 | $0.00 |
| Grant/Award | Common Stock F1 | 9,650 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 19,300 contracts (Direct);
Common Stock — 9,650 shares (Direct)
Footnotes (2)
- F1. These shares represent restricted stock units (RSUs) granted under the Veradermics, Incorporated 2026 Incentive Plan. Each RSU represents a contingent right to receive one share of Common Stock. The RSUs vest as to 25% of the RSUs on each anniversary of the grant date (September 1, 2027, September 1, 2028, September 1, 2029, and September 1, 2030), subject to continued service.
- F2. The option vests as to 25% of the underlying shares of Common Stock on September 1, 2027, the first anniversary of the vesting commencement date, and as to the remaining shares, in equal monthly installments over 36 months thereafter, subject to continued service.
Key Figures
RSUs granted: 9,650 shares
Stock options granted: 19,300 shares
Option exercise price: $97.51 per share
+5 more
8 metrics
RSUs granted
9,650 shares
Restricted stock units of Common Stock granted September 1, 2026
Stock options granted
19,300 shares
Option to purchase Common Stock granted September 1, 2026
Option exercise price
$97.51 per share
Exercise price for 19,300-share stock option
RSU vesting schedule
25% each year 2027–2030
RSUs vest on September 1, 2027, 2028, 2029, and 2030, subject to service
Initial option vesting
25% on September 1, 2027
First vesting date for the option grant
Remaining option vesting period
36 months
Remaining option shares vest in equal monthly installments after first anniversary
Option expiration
September 1, 2036
Expiration date of the 19,300-share option grant
Shares held following RSU grant
9,650 shares
Common Stock reported as held directly after RSU grant
Key Terms
restricted stock units (RSUs), Incentive Plan, vesting commencement date, equal monthly installments, +1 more
5 terms
restricted stock units (RSUs) financial
"These shares represent restricted stock units (RSUs) granted under the Veradermics"
Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.
Incentive Plan financial
"RSUs granted under the Veradermics, Incorporated 2026 Incentive Plan"
vesting commencement date financial
"first anniversary of the vesting commencement date, and as to the remaining"
The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.
equal monthly installments financial
"and as to the remaining shares, in equal monthly installments over 36 months"
exercise price financial
"conversion_or_exercise_price": "97.5100""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What equity awards did MANE grant to Chief R&D Officer David Hollander on September 1, 2026?
He received 9,650 RSUs of Common Stock and a stock option for 19,300 shares at an exercise price of $97.51 per share, all held directly, as reported by Veradermics, Inc.
How do the 9,650 RSUs granted by MANE to the Chief R&D Officer vest?
The 9,650 RSUs vest as to 25% on each anniversary of the grant date: September 1, 2027, 2028, 2029, and 2030, subject to continued service with Veradermics, Inc.
What is the exercise price and expiration date of the Veradermics (MANE) option grant?
The stock option granted to the Chief R&D Officer covers 19,300 shares of Common Stock at an exercise price of $97.51 per share and expires on September 1, 2036, as disclosed by Veradermics, Inc.
Are the MANE equity awards to the Chief R&D Officer immediately exercisable or fully vested?
No. The RSUs vest in four annual 25% installments from September 1, 2027 through 2030, and the option vests 25% on September 1, 2027 with the remainder vesting monthly over 36 months, all subject to continued service.
Were the MANE transactions reported under a Rule 10b5-1 trading plan?
No. The filing indicates no Rule 10b5-1 plan is reported for these equity award transactions to the Chief R&D Officer of Veradermics, Inc.
AI-generated analysis. How Rhea-AI works. Not financial advice.
